Pembrolizumab Plus Olaparib for Previously Treated, Biomarker-Unselected, Metastatic Castration-Resistant Prostate Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial
J. Clin. Oncol 2023 Jun 08;[EPub Ahead of Print], ES Antonarakis, SH Park, JC Goh, SJ Shin, JL Lee, N Mehra, R McDermott, N Sala-Gonzalez, PC Fong, R Greil, M Retz, JP Sade, P Yanez, YH Huang, SD Begbie, RA Gafanov, M De Santis, E Rosenbaum, MP Kolinsky, F Rey, KY Chiu, G Roubaud, G Kramer, M Sumitomo, F Massari, H Suzuki, P Qiu, J Zhang, J Kim, CH Poehlein, EY YuFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.